KR102161866B1 - 카바지탁셀 및 설포부틸에테르 베타-사이클로덱스트린 조성물 - Google Patents

카바지탁셀 및 설포부틸에테르 베타-사이클로덱스트린 조성물 Download PDF

Info

Publication number
KR102161866B1
KR102161866B1 KR1020157020157A KR20157020157A KR102161866B1 KR 102161866 B1 KR102161866 B1 KR 102161866B1 KR 1020157020157 A KR1020157020157 A KR 1020157020157A KR 20157020157 A KR20157020157 A KR 20157020157A KR 102161866 B1 KR102161866 B1 KR 102161866B1
Authority
KR
South Korea
Prior art keywords
cabazitaxel
composition
cyclodextrin
solution
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157020157A
Other languages
English (en)
Korean (ko)
Other versions
KR20150127035A (ko
Inventor
발레리 알라크호브
그레체고로츠 피어진스키
키쇼어 파텔
Original Assignee
소프트케모 파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소프트케모 파마 코포레이션 filed Critical 소프트케모 파마 코포레이션
Publication of KR20150127035A publication Critical patent/KR20150127035A/ko
Application granted granted Critical
Publication of KR102161866B1 publication Critical patent/KR102161866B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157020157A 2012-12-24 2013-12-23 카바지탁셀 및 설포부틸에테르 베타-사이클로덱스트린 조성물 Active KR102161866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
US61/848,172 2012-12-24
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (2)

Publication Number Publication Date
KR20150127035A KR20150127035A (ko) 2015-11-16
KR102161866B1 true KR102161866B1 (ko) 2020-10-05

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020157A Active KR102161866B1 (ko) 2012-12-24 2013-12-23 카바지탁셀 및 설포부틸에테르 베타-사이클로덱스트린 조성물

Country Status (16)

Country Link
US (1) US9919053B2 (https=)
EP (1) EP2934593B1 (https=)
JP (1) JP6498610B2 (https=)
KR (1) KR102161866B1 (https=)
CN (1) CN105142671B (https=)
AU (1) AU2013377404B2 (https=)
BR (1) BR112015015202B8 (https=)
CA (1) CA2900508C (https=)
DK (1) DK2934593T3 (https=)
ES (1) ES2771423T3 (https=)
HU (1) HUE048505T2 (https=)
MX (1) MX371067B (https=)
PL (1) PL2934593T3 (https=)
PT (1) PT2934593T (https=)
RU (1) RU2678772C2 (https=)
WO (1) WO2014122498A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技(广州)有限公司 一种注射用卡巴他赛组合物及其制备方法
EP3827822B1 (en) * 2018-07-25 2024-11-06 Bika Biotechnology (Guangzhou) Co., Ltd. Docetaxel composition for injection and preparation method therefor
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443969A2 (en) * 2001-10-18 2004-08-11 Decode Genetics EHF Non-inclusion cyclodextrin complexes
JP2005022989A (ja) * 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
RU2426590C2 (ru) * 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
WO2005042584A2 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
WO2013024495A1 (en) 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery

Also Published As

Publication number Publication date
WO2014122498A3 (en) 2014-12-04
MX2015008225A (es) 2016-07-20
EP2934593A4 (en) 2016-08-10
EP2934593B1 (en) 2020-02-05
DK2934593T3 (da) 2020-02-17
PL2934593T3 (pl) 2020-05-18
AU2013377404A2 (en) 2015-08-27
US20150328321A1 (en) 2015-11-19
RU2678772C2 (ru) 2019-02-01
CA2900508A1 (en) 2014-08-14
BR112015015202B8 (pt) 2022-02-15
JP6498610B2 (ja) 2019-04-10
WO2014122498A2 (en) 2014-08-14
AU2013377404A1 (en) 2015-07-30
CN105142671B (zh) 2018-09-14
ES2771423T3 (es) 2020-07-06
PT2934593T (pt) 2020-03-09
KR20150127035A (ko) 2015-11-16
AU2013377404B2 (en) 2018-08-23
CN105142671A (zh) 2015-12-09
MX371067B (es) 2020-01-15
CA2900508C (en) 2021-04-13
US9919053B2 (en) 2018-03-20
RU2015130495A (ru) 2017-01-27
JP2016508138A (ja) 2016-03-17
BR112015015202A2 (pt) 2017-07-11
BR112015015202B1 (pt) 2021-12-21
HUE048505T2 (hu) 2020-07-28
EP2934593A2 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
WO2018233095A1 (zh) 具有淋巴靶向功能的生物自组装纳米晶注射剂及制备方法
US20150064283A1 (en) Pharmaceutical compositions for parenteral administration
KR101395858B1 (ko) 다당류 리포솜, 이의 제조 방법 및 용도
KR102161866B1 (ko) 카바지탁셀 및 설포부틸에테르 베타-사이클로덱스트린 조성물
KR101807903B1 (ko) 음이온-양이온성 환형다당류 조성물인 벤다무스틴
CN106913882A (zh) 一种聚乙二醇‑藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
CN100577177C (zh) 一种替尼泊苷的药用组合物、制备方法及用途
CN104027307A (zh) 药物组合物及其制备方法
WO2003099288A1 (en) Medicinal composition
CN104511022A (zh) 一种紫杉醇的药物组合物
JP7267640B2 (ja) 希釈安定性に優れたテニポシド注射用溶液及びその調製方法
CN103405396B (zh) 一种含蓬莪术环二烯的药物组合物及其制药用途
CN101062028B (zh) 一种含紫杉烷类化合物的组合物、其制备方法和用途
CN104771371B (zh) 4-(3,5-二甲氧苯基)-5-(3-羟基-4-甲氧基苯基)咪唑制剂
WO2024011169A1 (en) Stable, liquid pharmaceutical compositions comprising melphalan
CN102327219B (zh) 一种埃索美拉唑镁脂质体固体制剂
CN103385851A (zh) 用于抗癌的可注射用药物组合物
HK40033919A (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40033919B (en) Pharmaceutical composition of docetaxel conjugate and preparation method

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000